Nishita Kalepalli

Oct 30, 2024 | medrxiv.org | Neil Kelly |Rahul Chaudhary |Wadih El Khoury |Nishita Kalepalli

S.Y.C. has served as a consultant for Merck, Janssen, and United Therapeutics; S.Y.C. is a director, officer, and shareholder in Synhale Therapeutics; S.Y.C. holds research grants from United Therapeutics, Bayer, and WoodNext Foundation. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension. Other authors: none.